2015—2019年北京地区醒脑静注射液临床应用不良反应分析  被引量:6

Analysis of adverse drug reaction in clinical application induced by Xingnaojing injection in Beijing from 2015 to 2019

在线阅读下载全文

作  者:张琳[1] 赵杰 魏娟娟[1] 石秀锦[1] 林阳[1] Zhang Lin;Zhao Jie;Wei Juanjuan;Shi Xiujin;Lin Yang(Department of Pharmacy,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China;Beijing Center for ADR Momitoring,Beijing 100035,China)

机构地区:[1]首都医科大学附属北京安贞医院药事部,100029 [2]北京市药品不良反应监测中心,100035

出  处:《中国医药》2020年第9期1449-1452,共4页China Medicine

基  金:国家卫生计生委“重大新药创制”科技重大专项(2017ZX09304017)。

摘  要:目的探讨醒脑静注射液相关药品不良反应(ADR)的临床特点和原因。方法收集北京市ADR监测中心数据库2015—2019年发生醒脑静注射液相关ADR 249例患者的临床资料,回顾性分析患者的报告年度、性别、年龄、药物及食物过敏史、原患疾病构成、发生时间、累及系统/器官和临床表现、ADR严重程度和转归,对疾病的影响以及醒脑静注射液的用法用量和合并用药情况。结果 249例患者中男86例,女163例;高发年龄为50~79岁,共163例(65.5%)。2017年报告的数量最多,为86例(34.5%);16例(6.4%)患者既往存在药物及食物过敏史;原患疾病以脑血管病最多,为125例(50.2%);160例(64.3%) ADR发生在用药的第1天内。249例患者共发生404例次ADR,累及皮肤及其附件79例次,主要临床表现为皮疹56例次,累及中枢及外周神经系统66例次,主要临床表现为头晕头痛51例次;严重ADR9例,一般ADR 240例(96.4%);痊愈94例,好转145例,未好转3例,死亡1例,不详6例。ADR使原患疾病病程延长5例,病情加重1例,死亡1例,其余242例影响不明显;36例(14.5%)患者单次给药剂量为30~40 ml,2例用药疗程> 14 d;合并用药86例(34.5%)。结论醒脑静注射液相关ADR患者以女性较多见、中老年人高发,原患疾病多为脑血管病,多发生在用药第1天内,常累及皮肤及其附件和中枢及外周神经系统,临床超说明书用药情况包括单次给药剂量增加、用药疗程延长和儿童用药,临床应加强醒脑静注射液合理用药监管,加强对其相关ADR的识别及救治能力。Objective To investigate the clinical characteristics and causes of adverse drug reactions( ADR) induced by Xingnaojing injection. Methods From 2015 to 2019,clinical data of 249 patients with ADR related to Xingnaojing injection were collected from the database of Beijing Center for ADR Monitoring. The clinical data including the reporting year,gender,age,history of drug and food allergy,composition of original disease,occurrence time,involved system/organ and clinical manifestations,severity and prognosis of ADRs and its influence on the original disease,usage and dosage of Xingnaojing injection and combined medications were analyzed retrospectively. Results Among 249 patients,86 were male and 163 were female;the high incidence age of ADR was 50-79 years[163 cases( 65. 5%) ]. In 2017,the number of reports was the largest [86 cases( 34. 5%) ];16 cases( 6. 4%) had a history of drug and food allergy;the most common primary disease was cerebrovascular disease( 125 cases,50. 2%);160 cases( 64. 3%) occurred within the first day. A total of 404 ADR occurred in 249 patients,systems and organs affected by ADR were mainly observed to be skin and appendages disorders( 79 cases),the clinical manifestations were rash( 56 cases),central and peripheral nervous system in66 cases,dizziness and headache( 51 cases). There were 9 cases of severe ADR and 240 cases( 96. 4%) of general ADR;94 cases were cured,145 cases were improved,3 cases were not improved,1 case died and 6 cases were unknown;ADR prolonged the course of disease in 5 cases,aggravated in 1 case,died in 1 case,and the other 242 cases had no obvious effect;36 patients( 14. 5%) received a single dose of 30-40 ml,2 patients were treated for more than 14 d,and 86 patients( 34. 5%) were combined with medication. Conclusions Xingnaojing injection-related ADR are more common in female,with high incidence in middle-aged and elderly people. The primary disease is cerebrovascular disease and often occurs within the first day of medication. It often affects the skin and its appen

关 键 词:药品不良反应 醒脑静注射液 用药分析 

分 类 号:R969[医药卫生—药理学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象